GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting

Abstract

Patients benefit from teduglutide in a real-life setting, but in contrast to randomized, controlled studies reduction of parenteral support took longer. We identified early clinical markers of response, such as stool consistency and frequency as well as sensation of thirst. Clinical and molecular observations support the role of the colon as an important target organ of teduglutide.